Mga Batayang Estadistika
| LEI | 2549007HE5QY1QEQ8K43 |
| CIK | 727207 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Accelerate Diagnostics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE Exhibit 10.2 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE ) In re: ) Chapter 11 ) ACCELERATE DIAGNOSTICS, INC., et al.,1 ) ) Case No. 25-10837 (KBO) Debtors. ) (Jointly Administered) ) ) Ref. Docket Nos. 155, 167 & 214 FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER APPROVING ADEQUACY OF DISCLOSURES ON A FINAL BASIS AND CONFIRMING THE SECOND AMENDED COMBINED DISCLOSURE S |
|
| August 18, 2025 |
Exhibit 10.1 Execution Version AMENDED and Restated ASSET PURCHASE AGREEMENT by and among Accelerate Diagnostics, Inc., Accelerate Diagnostics Texas, LLC, and Indaba Starling, LLC Dated as of August 8, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 1.1 Certain Defined Terms 2 1.2 Construction 19 ARTICLE II SALE AND PURCHASE OF ASSETS; LIABILITIES 20 2.1 Sale of Purchased Assets 20 2.2 Liabili |
|
| August 18, 2025 |
SEC FILE NUMBER 001-31822 CUSIP NUMBER 00430H201 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| June 4, 2025 |
Exhibit 10.1 Execution Version ASSET PURCHASE AGREEMENT by and between Accelerate Diagnostics, Inc., Accelerate Diagnostics Texas, LLC, and Indaba Starling, LLC Dated as of May 30, 2025 TABLE OF CONTENTS Page Article I DEFINITIONS 1 1.1 Certain Defined Terms 1 1.2 Construction 18 Article II SALE AND PURCHASE OF ASSETS; LIABILITIES 19 2.1 Sale of Purchased Assets 19 2.2 Liabilities 23 2.3 Considera |
|
| June 4, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 30, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 21, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 16, 2025 |
SEC FILE NUMBER 001-31822 CUSIP NUMBER 00430H201 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 12, 2025 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| May 8, 2025 |
Exhibit 10.2 Execution Version ACCELERATE DIAGNOSTICS, INC. SUMMARY OF TERMS AND CONDITIONS Senior Secured SuperPriority Debtor-In-Possession Credit Facility This Summary of Terms and Conditions (the “DIP Term Sheet”) describes the terms and conditions of a multi-draw senior secured super-priority priming term loan debtor-in-possession credit facility in the aggregate principal amount of up to app |
|
| May 8, 2025 |
Exhibit 99.1 Accelerate Diagnostics Files for Chapter 11 Protection and Agrees to Terms to Sell Substantially All Assets TUCSON, Ariz., May 8, 2025 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (“Accelerate” or the Company”) today announced that it has voluntarily initiated a Chapter 11 restructuring proceeding in the United States Bankruptcy Court for the District of Delaware (“Bankruptcy Court”) |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| May 8, 2025 |
Accelerate Diagnostics, Inc. – Stalking Horse Term Sheet Exhibit 10.1 Execution Version Accelerate Diagnostics, Inc. – Stalking Horse Term Sheet THIS SUMMARY OF TERMS AND CONDITIONS (THIS “STALKING HORSE TERM SHEET”) SETS FORTH THE PRINCIPAL TERMS OF A PROPOSED SALE TRANSACTION (THE “SALE”) BETWEEN THE PARTIES DESCRIBED HEREIN. THIS STALKING HORSE TERM SHEET SHALL BE BINDING ON THE PARTIES UPON EXECUTION BY THE COMPANY AND THE STALKING HORSE BIDDER. THI |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31822 ACCELERATE |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 22, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 10, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| March 21, 2025 |
EXHIBIT 10.5.4 ACCELERATE DIAGNOSTICS, INC. 2022 OMNIBUS EQUITY INCENTIVE PLAN NOTICE OF GRANT OF NONQUALIFIED STOCK OPTIONS This Nonqualified Stock Option Agreement consists of this Notice of Grant of Nonqualified Stock Options (the “Grant Notice”) and the Nonqualified Stock Option Award Agreement immediately following. The Nonqualified Stock Option Agreement sets forth the specific terms and con |
|
| March 21, 2025 |
Accelerate Diagnostics, Inc. Insider Trading Policy EXHIBIT 19 ACCELERATE DIAGNOSTICS, INC. INSIDER TRADING POLICY This Insider Trading Policy (“Policy”) provides the standards of Accelerate Diagnostics, Inc. (“Accelerate”) on trading and causing the trading of Accelerate’s securities or securities of other publicly traded companies while in possession of confidential information. This Policy prohibits trading in certain circumstances and applies t |
|
| March 21, 2025 |
EXHIBIT 21 ACCELERATE DIAGNOSTICS, INC. LIST OF SUBSIDIARIES Legal Entity Jurisdiction/Domicile Accelerate Diagnostics UK Limited England Accelerate Diagnostics S.L. Spain Accelerate Diagnostics GmbH Germany Accelerate Diagnostics SARL France Accelerate Diagnostics S.r.l Italy Accelerate Diagnostics Pty Ltd Australia Accelerate Diagnostics B.V. Netherlands Accelerate Diagnostics Holdings, LLC Unit |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of regi |
|
| March 21, 2025 |
Exhibit 99.1 Accelerate Diagnostics Submits WAVE System and Gram-Negative Positive Blood Culture Menu to the FDA for 510(k) Clearance TUCSON, Ariz., March 21, 2025 (NASDAQ: AXDX), an innovator in rapid in vitro diagnostics for microbiology, today announced the submission of its Accelerate WAVE™ system and positive blood culture gram-negative test kit to the U.S. Food and Drug Administration (FDA) |
|
| March 21, 2025 |
EXHIBIT 10.5.3 ACCELERATE DIAGNOSTICS, INC. 2022 OMNIBUS EQUITY INCENTIVE PLAN NOTICE OF GRANT OF RESTRICTED STOCK UNITS This Restricted Stock Unit Agreement consists of this Notice of Grant of Restricted Stock Units (the “Grant Notice”) and the Restricted Stock Unit Award Agreement immediately following. The Restricted Stock Unit Agreement sets forth the specific terms and conditions governing Re |
|
| March 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| March 21, 2025 |
ACCELERATE DIAGNOSTICS, INC. BALANCE SHEETS (in thousands, except share data) Exhibit 99.1 Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2024 Financial Results TUCSON, Ariz., March 21, 2025 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today reports financial results for the fourth quarter and year ended December 31, 2024. 2024 Fourth Quarter Results · Net sales for the quarter were $2.8 million, compared to $3.0 million for the same quarter of the prior year. |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 28, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commi |
|
| January 10, 2025 |
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results Exhibit 99.1 Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2024 Results TUCSON, Ariz., January 10, 2025 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain prel |
|
| January 10, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 10, 2025 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commi |
|
| December 5, 2024 |
AXDX / Accelerate Diagnostics, Inc. / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
AXDX / Accelerate Diagnostics, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-axdx093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ACCELERATE DIAGNOSTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 00430H201 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 7, 2024 |
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) Exhibit 99.1 Accelerate Diagnostics Reports Third Quarter 2024 Financial Results TUCSON, Ariz., November 7, 2024 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2024. “We are excited by the momentum we’re building across our innovation pipeline, underscored by the successful launch of the clinical trial for our WAVETM system |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCEL |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commi |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Com |
|
| September 30, 2024 |
Exhibit 99.1 Accelerate Diagnostics Announces FDA Clearance of its Accelerate Arc™ System An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples Tucson, Ariz. (September 30, 2024) – Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 26, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commis |
|
| August 12, 2024 |
AXDX / Accelerate Diagnostics, Inc. / Indaba Capital Management, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Accelerate Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00430H102 (CUSIP Number) Zac Ro |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| August 8, 2024 |
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) Exhibit 99.1 Accelerate Diagnostics Reports Second Quarter 2024 Financial Results TUCSON, Ariz., August 8, 2024 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024. During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVETM System and Gram-Negative Positive Blood Culture (PB |
|
| August 8, 2024 |
Exhibit 10.1 EXECUTION VERSION NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”), dated as of August 8, 2024, is made by and among Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the investors identified on Annex I attached hereto (together with their respective successors and permitted assigns, the “Investors”). WHEREAS, the Company and the Investor |
|
| August 8, 2024 |
Exhibit 10.2 Execution Version FIRST LIEN/SECOND LIEN INTERCREDITOR AGREEMENT among U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Senior Priority Representative for the Super-Priority Secured Parties and Super-Priority Collateral Agent, U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Second Priority Representative for the Initial Second Priority Debt Secured Parties and Second Priority Colla |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCELERATE |
|
| August 8, 2024 |
Exhibit 4.1 Execution Version ACCELERATE DIAGNOSTICS, INC. as Issuer, THE GUARANTORS NAMED HEREIN and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee and as Notes Collateral Agent INDENTURE Dated as of August 8, 2024 $15,000,000 Super-Priority Senior Secured PIK Notes Due 2025 Table of Contents Page Article One DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION Section 1.01. Rules of |
|
| August 8, 2024 |
Exhibit 10.3 Execution Version SUPER-PRIORITY SECURITY AGREEMENT among ACCELERATE DIAGNOSTICS, INC., as Issuer, and THE GUARANTORS PARTY HERETO FROM TIME TO TIME, as Guarantors and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Collateral Agent Dated as of August 8, 2024 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATION 1 SECTION 1.1 Definitions 1 SECTION 1.2 Interpretation 7 SECT |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 5, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| June 3, 2024 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| June 3, 2024 |
Letter of Ernst & Young LLP, dated June 3, 2024 Exhibit 16.1 June 3, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated June 3, 2024, of Accelerate Diagnostics, Inc. and are in agreement with the statements contained in the last sentence of the first paragraph insofar as it relates to the date of notification of our dismissal and paragraphs 2, 3, 4 and 5 on pag |
|
| May 31, 2024 |
Exhibit 1.01 Accelerate Diagnostics, Inc. Conflict Minerals Report For The Year Ended December 31, 2023 This Conflict Minerals Report for the year ended December 31, 2023, is submitted by Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) as required by Section 13(p) of, and Rule 13p-1 under, the Securities Exchange Act of 1934, as amended (the “Conflict Regulations”). 1.Company Overview |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM SD Specialized Disclosure Report ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31822 84-1072256 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Accelerate Diagnostics, Inc. 3950 South Country Club Road, Suite 470 |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 29, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 23, 2024 |
AXDX / Accelerate Diagnostics, Inc. / SCHULER JACK W Activist Investment SC 13D/A 1 axdx13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* Accelerate Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00430H201 (Cusip Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224) 880-1210 |
|
| May 22, 2024 |
Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 15, 2024 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Accelerate Diagnostics, Inc. |
|
| May 15, 2024 |
As filed with the Securities and Exchange Commission on May 14, 2024 As filed with the Securities and Exchange Commission on May 14, 2024 Registration No. |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 7, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| May 13, 2024 |
Second Amendment to the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan Exhibit 10.1 SECOND AMENDMENT TO THE ACCELERATE DIAGNOSTICS, INC. 2022 OMNIBUS EQUITY INCENTIVE PLAN Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), established, and the shareholders approved, the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan (the “Plan”) effective as of May 12, 2022. The Plan was subsequently amended by the First Amendment, effective as of |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCELERAT |
|
| May 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84 |
|
| May 10, 2024 |
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) Exhibit 99.1 ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS Unaudited (in thousands, except share data) March 31, December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 14,606 $ 12,138 Investments 1,145 1,081 Trade accounts receivable 2,217 2,622 Inventory 3,249 3,310 Prepaid expenses 1,068 380 Purchase obligation put option asset — 3,419 Other current assets |
|
| May 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| May 8, 2024 |
ACCELERATE DIAGNOSTICS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share data) Exhibit 99.1 Accelerate Diagnostics Reports Preliminary First Quarter 2024 Financial Results TUCSON, Ariz., May 8, 2024 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial preliminary results for the first quarter ended March 31, 2024. “During the quarter we installed our first pre-clinical trial site demonstrating our ability to successfully ship, install, train and run the Ac |
|
| April 30, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 26, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| March 29, 2024 |
EXHIBIT 4.6 DESCRIPTION OF OUR SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General As of December 31, 2023, Accelerate Diagnostics, Inc. (“we”, “us” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. Our authorized capital stock consists of 455,00 |
|
| March 29, 2024 |
Reichling Consulting Services Agreement Exhibit 10.17 ATTACHMENT B CONSULTING SERVICES AGREEMENT THIS Consulting Services Agreement (“Agreement”) is entered into as of March 9, 2023 with an effective date of April 3, 2023 (“Effective Date”) by and between Accelerate Diagnostics, Inc., 3950 S. Country Club Road, Suite 470, Tucson, AZ 85714 (“Accelerate”), and Steve Reichling having an address at 12598 North Yellow Bird Road, Oro Valley A |
|
| March 29, 2024 |
Mertz Change in Employment Status Agreement 4:) /\CCELER/\TE • UIAL.iNUSllLS June 23, 2022 Lawrence Mertz Delivered Electronically via Email Re: Change in Employment Status Dear Larry: Congratulations! We are delighted to enter into this Letter Agreement (the" Agreement") to memorialize the terms under which you will serve first as an employee of Accelerate Diagnostics, Inc. (the "Company") as Chief Technological Officer of the Company. The |
|
| March 29, 2024 |
Fourth Quarter and Full Year 2023 Earnings Call Exhibit 99.2 Accelerate Diagnostics, Inc. Fourth Quarter and Full Year 2023 Earnings Call Thursday, March 28, 2024, 4:30 PM Eastern CORPORATE PARTICIPANTS Jack Phillips - President, Chief Executive Officer David Patience - Chief Financial Officer Laura Pierson - Investor Relations 1 PRESENTATION Operator Hello, welcome to the Accelerate Diagnostics' Fourth Quarter and Full Year 2023 Earnings Call. |
|
| March 29, 2024 |
EXHIBIT 97 ACCELERATE DIAGNOSTICS, INC. Clawback Policy for the Recovery of Erroneously Awarded Compensation In accordance with the applicable rules of The Nasdaq Stock Market (the “NASDAQ Rules”), Section 10D and Rule 10D-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”), the Board of Directors (the “Board”) of Accelerate Diagnostics, Inc. (“Accelerate”) has |
|
| March 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| March 29, 2024 |
EXHIBIT 21 ACCELERATE DIAGNOSTICS, INC. LIST OF SUBSIDIARIES Legal Entity Jurisdiction/Domicile Accelerate Diagnostics UK Limited England Accelerate Diagnostics S.L. Spain Accelerate Diagnostics GmbH Germany Accelerate Diagnostics SARL France Accelerate Diagnostics S.r.l Italy Accelerate Diagnostics Pty Ltd Australia Accelerate Diagnostics B.V. Netherlands Accelerate Diagnostics Holdings, LLC Unit |
|
| March 29, 2024 |
ACCELERATE DIAGNOSTICS, INC. BALANCE SHEETS (in thousands, except share data) Exhibit 99.1 Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2023 Financial Results TUCSON, Ariz., March 28, 2024 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023. “In 2023, we made significant progress with the development of our next-generation rapid Antibiotic Susceptibility Testing system, Accele |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of regi |
|
| March 5, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 4, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissi |
|
| January 25, 2024 |
Form of Subscription Agreement Exhibit 10.1 FORM OF SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into this 19th day of January, 2024, by and between Accelerate Diagnostics, Inc., a Delaware corporation (the “Issuer”), and the undersigned (“Subscriber” or “you”). WHEREAS, Subscriber desires to subscribe for and purchase from the Issuer that number of shares of the Issuer’s common |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-31822 84-1072256 (State or other jurisdiction of incorporation or org |
|
| January 25, 2024 |
Exhibit 4.1 WARRANT AGENCY AGREEMENT Broadridge Corporate Issuer Solutions, LLC and Accelerate Diagnostics, Inc. WARRANT AGENCY AGREEMENT made as of January 23, 2024 (the “Issuance Date”), between Accelerate Diagnostics, Inc., a Delaware corporation with offices at 3950 S. Country Club Road, Suite 470, Tucson, Arizona 85714 (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, with offi |
|
| January 23, 2024 |
TABLE OF CONTENTS PROSPECTUS 5,515,767 Units Each Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock 1,344,892 Pre-Funded Units Each Consisting of One Pre-Funded Warrant to Purchase One Share of Common Stock and One Warrant to Purchase One Share of Common Stock Up to 8,205,551 Shares of Common Stock Underlying the Warrants and the Pre-Funded Warrants Accelerate Diagnostics, Inc. |
|
| January 18, 2024 |
Form of Warrant Agency Agreement Exhibit 4.8 WARRANT AGENCY AGREEMENT Broadridge Corporate Issuer Solutions, LLC and Accelerate Diagnostics, Inc. WARRANT AGENCY AGREEMENT made as of [Issuance Date] (the “Issuance Date”), between Accelerate Diagnostics, Inc., a Delaware corporation with offices at 3950 S. Country Club Road, Suite 470, Tucson, Arizona 85714 (the “Company”), and Broadridge Corporate Issuer Solutions, LLC, with offic |
|
| January 18, 2024 |
January 18, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attn: Katherine Bagley Re: Accelerate Diagnostics, Inc. Registration Statement on Form S-1 File No. 333-276031 Acceleration Request Requested Date: January 18, 2024 Requested Time: 4:00 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under |
|
| January 18, 2024 |
Exhibit 4.6 WARRANT TO PURCHASE STOCK Company: Accelerate Diagnostics, Inc., a Delaware corporation Warrant No. 2024-[●] Number of Shares: [●], subject to adjustment Type/Series of Stock: Common stock, $0.001 par value per share (the “Common Stock”) Warrant Price (“Exercise Price”): $[●] per Share, subject to adjustment Issue Date: [●], 2024 Expiration Date: [●], 2029 (See also Section 5.1(b).) TH |
|
| January 18, 2024 |
[Remainder of Page Intentionally Left Blank; Signature Page Follows] January 18, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Katherine Bagley Re: Accelerate Diagnostics, Inc. Registration Statement on Form S-1 File No. 333-276031 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the repre |
|
| January 18, 2024 |
Exhibit 4.7 PRE-FUNDED WARRANT TO PURCHASE STOCK Company: Accelerate Diagnostics, Inc., a Delaware corporation Warrant No. 2024-[●] Number of Shares: [●], subject to adjustment Type/Series of Stock: Common stock, $0.001 par value per share (the “Common Stock”) Warrant Price (“Exercise Price”): $0.01 per Share, subject to adjustment Issue Date: [●], 2024 THIS PRE-FUNDED WARRANT CERTIFIES THAT, for |
|
| January 18, 2024 |
As filed with the Securities and Exchange Commission on January 18, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 18, 2024 Registration No. |
|
| January 16, 2024 |
Exhibit 4.7 PRE-FUNDED WARRANT TO PURCHASE STOCK Company: Accelerate Diagnostics, Inc., a Delaware corporation Warrant No. 2024-[●] Number of Shares: [●], subject to adjustment Type/Series of Stock: Common stock, $0.001 par value per share (the “Common Stock”) Warrant Price (“Exercise Price”): $0.01 per Share, subject to adjustment Issue Date: [●], 2024 THIS PRE-FUNDED WARRANT CERTIFIES THAT, for |
|
| January 16, 2024 |
Form of Underwriting Agreement Exhibit 1.1 ACCELERATE DIAGNOSTICS, INC. [] Shares of Common Stock Pre-Funded Warrants to Purchase [] Shares of Common Stock Warrants to Purchase [] Shares of Common Stock Underwriting Agreement [], 2024 William Blair & Company, L.L.C. 150 N. Riverside Plaza Chicago, IL 60606 As representative of the several Underwriters named in Schedule I hereto, c/o William Blair & Company, L.L.C. 150 N. Rivers |
|
| January 16, 2024 |
As filed with the Securities and Exchange Commission on January 16, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on January 16, 2024 Registration No. |
|
| January 16, 2024 |
Exhibit 4.6 WARRANT TO PURCHASE STOCK Company: Accelerate Diagnostics, Inc., a Delaware corporation Warrant No. 2024-[●] Number of Shares: [●], subject to adjustment Type/Series of Stock: Common stock, $0.001 par value per share (the “Common Stock”) Warrant Price (“Exercise Price”): $[●] per Share, subject to adjustment Issue Date: [●], 2024 Expiration Date: [●], 2029 (See also Section 5.1(b).) TH |
|
| January 16, 2024 |
Form of Warrant Agency Agreement Exhibit 4.8 FORM OF WARRANT AGENCY AGREEMENT Broadridge Corporate Issuer Solutions, Inc. and Accelerate Diagnostics, Inc. WARRANT AGENCY AGREEMENT made as of [Issuance Date] (the “Issuance Date”), between Accelerate Diagnostics, Inc., a Delaware corporation, with offices at Accelerate Diagnostics, Inc., a Delaware corporation with offices at 3950 S. Country Club Road, Suite 470, Tucson, Arizona 85 |
|
| January 8, 2024 |
Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results Exhibit 99.1 Accelerate Diagnostics Announces Certain Preliminary Fourth Quarter and Full-Year 2023 Results TUCSON, Ariz., January 7, 2024 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preli |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 7, 2024 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commis |
|
| December 13, 2023 |
Exhibit 99.1 December 2023 Company Presentation 1 Legal Disclaimer Forward-Looking Statements This presentation contains, and the Company’s responses to various questions from investors may include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “ |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 11, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Comm |
|
| December 13, 2023 |
Exhibit 10.1 FIRST AMENDMENT TO SECURITIES PURCHASE AGREEMENT Accelerate Diagnostics, Inc. and Jack W. Schuler Living Trust This amendment (this “Amendment”) to the Securities Purchase Agreement by and among Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the Jack W. Schuler Living Trust (including its successors and assigns, the “Investor”) dated as of June 9, 2023 (the |
|
| December 13, 2023 |
Exhibit 10.3 FIRST AMENDMENT TO Note Exchange AGREEMENT This First Amendment to Note Exchange Agreement (this “Amendment”), dated as of December 11, 2023, is entered into by and between Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the undersigned investors constituting Majority Investors. WHEREAS, reference is made to that certain Note Exchange Agreement, dated as of J |
|
| December 13, 2023 |
As filed with the Securities and Exchange Commission on December 13, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 13, 2023 Registration No. |
|
| December 13, 2023 |
Exhibit 10.2 FIRST AMENDMENT TO NOTE Purchase AGREEMENT This First Amendment to Note Purchase Agreement (this “Amendment”), dated as of December 11, 2023, is entered into by and between Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the undersigned investors constituting Majority Investors. WHEREAS, reference is made to that certain Note Purchase Agreement, dated as of J |
|
| December 13, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables FORM S-1 (Form Type) ACCELERATE DIAGNOSTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee(3) Car |
|
| November 27, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 27, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Comm |
|
| November 27, 2023 |
Exhibit 99.1 Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper® Working together to bring rapid, automated microbial identification directly from positive blood culture samples Tucson, Ariz. (November 27, 2023) – Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced t |
|
| November 9, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 9, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCEL |
|
| November 9, 2023 |
Accelerate Diagnostics Reports Third Quarter 2023 Results Exhibit 99.1 Accelerate Diagnostics Reports Third Quarter 2023 Results TUCSON, Ariz., November 9, 2023 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2023. “During the quarter we made significant advances with our Wave program” commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc. “We are getting |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCELERATE |
|
| August 10, 2023 |
Accelerate Diagnostics Reports Second Quarter 2023 Financial Results Exhibit 99.1 Accelerate Diagnostics Reports Second Quarter 2023 Financial Results TUCSON, Ariz., August 10, 2023 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2023. “Throughout the quarter, we’ve significantly advanced our Wave Program,” stated Jack Phillips, CEO of Accelerate Diagnostics, Inc. “Our recent achie |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 10, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commis |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 31, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissi |
|
| July 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 11, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissi |
|
| July 13, 2023 |
Certificate of Amendment to the Certificate of Incorporation of Registrant Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ACCELERATE DIAGNOSTICS, INC. Accelerate Diagnostics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: That the following resolutions were duly adopted by the Corporation’s Board of Directors, in ac |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 6, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| July 10, 2023 |
Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split Exhibit 99.1 Accelerate Diagnostics Announces 1-for-10 Reverse Stock Split TUCSON, Ariz., July 10, 2023 /PRNewswire/ - Accelerate Diagnostics, Inc., (NASDAQ:AXDX) (the “Company”) a leading provider of innovative rapid diagnostic solutions, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. The reverse stock split will become effec |
|
| June 21, 2023 |
As filed with the Securities and Exchange Commission on June 20, 2023 Registration No. |
|
| June 21, 2023 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Accelerate Diagnostics, Inc. |
|
| June 20, 2023 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of this Schedule 13D (including additional amendments thereto) with respect to the shares of common stock, par value $0.001 per share, of Accelerate Diagnostics, Inc. This |
|
| June 20, 2023 |
AXDX / Accelerate Diagnostics Inc / Indaba Capital Management, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Accelerate Diagnostics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 00430H102 (CUSIP Number) Zac Rosen |
|
| June 20, 2023 |
AXDX / Accelerate Diagnostics Inc / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 20, 2023 |
Exhibit 99.7 ACCELERATE DIAGNOSTICS, INC. June 9, 2023 Ladies and Gentlemen: Reference is hereby made to the $22,709,818.00 aggregate principal amount of the 5.00% Senior Secured Convertible Notes due 2026 (the “Notes”) issued by Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), pursuant to the Indenture, dated June 9, 2023 (the “Indenture”), by and between the Company and U.S. |
|
| June 13, 2023 |
Note Exchange Agreement, date June 9, 2023, between the Company and certain investors named therein. EX-10.1 3 tm2317532d3ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 Execution Version NOTE EXCHANGE AGREEMENT This Note Exchange Agreement (this “Agreement”), dated as of June 9, 2023, is made by and among Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the investors identified on Annex I attached hereto (together with their respective successors and permitted assigns, the “Investo |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| June 13, 2023 |
Exhibit 10.6 EXECUTION VERSION CONSENT AND AMENDMENT NO. 1 TO SECURED PROMISSORY NOTE This Consent and Amendment No. 1 to Secured Promissory Note (the “Consent and Amendment”) is entered into on June 9, 2023 between Accelerate Diagnostics, Inc., a Delaware corporation (the “Borrower”), and the Jack W. Schuler Living Trust (the “Holder”). WHEREAS, on August 15, 2022, the Borrower issued a Secured P |
|
| June 13, 2023 |
Note Purchase Agreement, dated June 9, 2023, between Registrant and certain investors named therein Exhibit 10.2 Execution Version NOTE PURCHASE AGREEMENT This Note Purchase Agreement (this “Agreement”), dated as of June 9, 2023, is made by and among Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the investors identified on Annex I attached hereto (together with their respective successors and permitted assigns, the “Investors”). WHEREAS, the Company and the Investo |
|
| June 13, 2023 |
EX-99.1 9 tm2317532d3ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ACCELERATE DIAGNOSTICS INVESTOR PRESNTATION Jack Phillips President & CEO Accelerate Diagnostics, Inc May 2023 The information contained herein has been prepared by Accelerate Diagnostics, Inc. and its affiliates (the “Company”) and is highly confidential and proprietary information and may not be disclosed by the recipient to any other per |
|
| June 13, 2023 |
Exhibit 10.7 EXECUTION VERSION AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT This Amendment No. 1 to Securities Purchase Agreement (the “Amendment”) is entered into on June 9, 2023 between Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the Jack W. Schuler Living Trust (the “Purchaser”). WHEREAS, on March 24, 2022, the Company entered into a Securities Purchase Agreeme |
|
| June 13, 2023 |
Exhibit 10.3 Execution Version SECURITY AGREEMENT among ACCELERATE DIAGNOSTICS, INC., as Issuer, and THE GUARANTORS PARTY HERETO FROM TIME TO TIME, as Guarantors and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Collateral Agent Dated as of June 9, 2023 TABLE OF CONTENTS Page Article I DEFINITIONS AND INTERPRETATION 1 SECTION 1.1 Definitions 1 SECTION 1.2 Interpretation 7 SECTION 1.3 Resolutio |
|
| June 13, 2023 |
Exhibit 10.8 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 9, 2023, by and between Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), and the Jack W. Schuler Living Trust, a living trust organized under the laws of the State of Illinois (the “Investor”). WHEREAS, the Company and the Investor desire to en |
|
| June 13, 2023 |
Exhibit 4.1 EXECution version ACCELERATE DIAGNOSTICS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee and Collateral Agent INDENTURE Dated as of June 9, 2023 5.00% Senior Secured Convertible Notes due 2026 Table of Contents Page Article 1 DEFINITIONS Section 1.01. Definitions 1 Section 1.02. References to Interest 17 Article 2 Issue, Description, Execution, Registration and Exch |
|
| June 8, 2023 |
AXDX / Accelerate Diagnostics Inc / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 6, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 2, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| June 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 31, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM SD Specialized Disclosure Report ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31822 84-1072256 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Accelerate Diagnostics, Inc. 3950 South Country Club Road, Suite 470 |
|
| May 31, 2023 |
EX-1.01 2 tm2317203d3ex1-01.htm EXHIBIT 1.01 Exhibit 1.01 Accelerate Diagnostics, Inc. Conflict Minerals Report For The Year Ended December 31, 2022 This Conflict Minerals Report for the year ended December 31, 2022 is submitted by Accelerate Diagnostics, Inc. (“Accelerate” or the “Company”) as required by Section 13(p) of, and Rule 13p-1 under, the Securities Exchange Act of 1934, as amended (the |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 26, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 30, 2023 |
As filed with the Securities and Exchange Commission on May 30, 2023 As filed with the Securities and Exchange Commission on May 30, 2023 Registration No. |
|
| May 24, 2023 |
First Amendment to the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan EXHIBIT 10.1 FIRST AMENDMENT TO THE ACCELERATE DIAGNOSTICS, INC. 2022 OMNIBUS EQUITY INCENTIVE PLAN Effective as of May 12, 2022, Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), established, and the shareholders approved, the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan (the “Plan”). By adoption of this instrument, the Company now desires to amend the Plan |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 24, 2023 |
Certificate of Amendment to the Certificate of Incorporation of Registrant EXHIBIT 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ACCELERATE DIAGNOSTICS, INC. Accelerate Diagnostics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies as follows: FIRST: That the following resolutions were duly adopted by the Corporation’s Board of Directors, in ac |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 16, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 15, 2023 |
Agreement between Registrant and David Patience, dated as of March 9, 2023 EXHIBIT 10.3 March 9, 2023 David Patience Delivered Electronically via Email Re: Change in Employment Status Dear David: Congratulations! We are delighted to enter into this Letter Agreement (the “Agreement”) to memorialize the terms under which you will serve first as an employee of Accelerate Diagnostics, Inc. (the “Company”) as Chief Financial Officer of the Company. The effective date of this |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCELERAT |
|
| May 11, 2023 |
Accelerate Diagnostics Reports First Quarter 2023 Financial Results Exhibit 99.1 Accelerate Diagnostics Reports First Quarter 2023 Financial Results TUCSON, Ariz., May 11, 2023 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2023. “Our first quarter results are in line with expectations, and I am optimistic about the remainder of 2023 and beyond,” commented Jack Phillips, Chief Ex |
|
| May 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 11, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy State |
|
| April 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 21, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| April 24, 2023 |
Exhibit 10.1 Execution Version [***] Portions of this exhibit have been redacted because it is both not material and is the type of information that the registrant treats as private or confidential. This RESTRUCTURING SUPPORT AGREEMENT and the documents attached hereto collectively describe a proposed restructuring of THE COMPANY PARTY THAT WILL BE EFFECTuatED either pursuant to an out-of-court ex |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 13, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) April 5, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission F |
|
| March 31, 2023 |
EXHIBIT 4.4 DESCRIPTION OF OUR CAPITAL STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General As of December 31, 2022, Accelerate Diagnostics, Inc. (“we”, “us” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. Our authorized capital stock consists of 205 |
|
| March 31, 2023 |
Subsidiaries of the Registrant EXHIBIT 21 ACCELERATE DIAGNOSTICS, INC. LIST OF SUBSIDIARIES Legal Entity Jurisdiction/Domicile Accelerate Diagnostics UK Limited England Accelerate Diagnostics S.L. Spain Accelerate Diagnostics GmbH Germany Accelerate Diagnostics SARL France Accelerate Diagnostics S.r.l Italy Accelerate Diagnostics Pty Ltd Australia Accelerate Diagnostics B.V. Netherlands Accelerate Diagnostics Holdings, LLC Unit |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of regi |
|
| March 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 23, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| March 29, 2023 |
Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results Exhibit 99.1 Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results TUCSON, Ariz., March 29, 2023 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2022. “In 2022, we achieved another year of revenue growth thanks to our base book of satisfied customers," commented Jack Phillips, Chief Exec |
|
| March 29, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 29, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| March 14, 2023 |
Exhibit 10.1 Execution Version FORBEARANCE AGREEMENT This Forbearance Agreement, dated as of March 9, 2023 (this “Agreement”), is entered into by and among (i) Accelerate Diagnostics, Inc., a Delaware corporation (the “Company”), (ii) Indaba Capital Management, L.P. (together with its affiliates, “Indaba”), (iii) Chicago Venture Partners, LP (“CVP”), (iv) RBC CMA LLC (“RBC”), (v) Penderfund Capita |
|
| March 14, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 9, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission F |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 9, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission F |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 21, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissi |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 6, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| January 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 16, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissi |
|
| January 11, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 5, 2023 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| December 13, 2022 |
Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (this “Agreement”) is entered into as of the date hereinafter set forth by and between Accelerate Diagnostics, Inc. (hereinafter “Company” or “Accelerate”), and Ron Price (“Employee”), referred to individually as a “Party” and collectively as the “Parties.” Whereas, Employee was hired by the Company on May 4, 2015, |
|
| December 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) December 8, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 14, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissi |
|
| November 15, 2022 |
Accelerate Diagnostics Reports Third Quarter 2022 Financial Results Exhibit 99.1 Accelerate Diagnostics Reports Third Quarter 2022 Financial Results TUCSON, Ariz., November 14, 2022 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter for the period ended September 30, 2022. “Our third quarter results were generally in line with my expectations,” commented Jack Phillips, Chief Executive Officer of Accelerate Diagnos |
|
| November 15, 2022 |
Exhibit 99.2 1 Accelerate Diagnostics, Inc. Third Quarter 2022 Earnings Monday, November 14, 2022, 4:30PM CORPORATE PARTICIPANTS Laura Pierson - IR Jack Phillips - President, CEO Steve Reichling - CFO Accelerate Diagnostics, Inc. Monday, November 14, 2022, 4:30PM 2 PRESENTATION Operator Good afternoon, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2022 Earnings Call. All participant |
|
| November 14, 2022 |
[***] Certain information in this document has been omitted pursuant to Regulation S-K, Item (601)(b)(10). |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCEL |
|
| October 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 21, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 29, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| August 23, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 17, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| August 23, 2022 |
Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock Exhibit 99.2 Accelerate Diagnostics Announces Pricing of Public Offering of Common Stock TUCSON, Ariz., August 18, 2022 (GLOBE NEWSWIRE) ? Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (?Accelerate Diagnostics?) today announced the pricing of an underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $2.00 per share. The gross proceeds to Accelerate Diagnost |
|
| August 23, 2022 |
Accelerate Diagnostics Announces Proposed Public Offering of Common Stock Exhibit 99.1 Accelerate Diagnostics Announces Proposed Public Offering of Common Stock TUCSON, Ariz., August 17, 2022 (GLOBE NEWSWIRE) ? Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (?Accelerate Diagnostics?) today announced that it has commenced an underwritten public offering of shares of its common stock. Accelerate Diagnostics expects to grant the underwriters a 30-day option to purchase up to |
|
| August 23, 2022 |
Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT ACCELERATE DIAGNOSTICS, INC. 17,500,000 Shares of Common Stock Underwriting Agreement August 18, 2022 William Blair & Company, L.L.C. As Representative of the several Underwriters listed in Schedule 1 hereto c/o William Blair & Company, L.L.C. 150 North Riverside Plaza Chicago, Illinois 60606 Ladies and Gentlemen: Accelerate Diagnostics, Inc., a |
|
| August 22, 2022 |
17,500,000 Shares Common Stock TABLE OF CONTENTS ? Filed Pursuant to Rule 424(b)(5)? ??Registration No. 333-252470? PROSPECTUS SUPPLEMENT (to prospectus dated February 4, 2021) 17,500,000 Shares Common Stock ? We are offering 17,500,000 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. ? Our common stock is listed on The Nasdaq Capital Market under the symbol ?AXDX.? On August 16 |
|
| August 18, 2022 |
SUBJECT TO COMPLETION, DATED AUGUST 17, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| August 15, 2022 |
Exhibit 10.1 Exchange Agreement August 15, 2022 Accelerate Diagnostics, Inc. 2.50% Convertible Senior Notes due 2023 The undersigned investor (the ?Exchanging Investor?), hereby agrees to exchange, with Accelerate Diagnostics, Inc., a Delaware corporation (the ?Company?), certain 2.50% Convertible Senior Notes due 2023, CUSIP 00430HAB8 (the ?Notes?) for the Exchange Consideration (as defined below |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCELERATE |
|
| August 15, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 15, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| August 15, 2022 |
Exhibit 10.4 security agreement This Security Agreement dated as of August 15, 2022 (?Security Agreement?), is made by and among Accelerate Diagnostics, Inc., a Delaware corporation (?Grantor?), and the secured party listed on the signature page hereto (the ?Secured Party?). Recitals A. The Secured Party has made and has agreed to make certain advances of money and to extend certain financial acco |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 15, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| August 15, 2022 |
Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR UNDER THE SECURITIES LAWS OF ANY STATES IN THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. T |
|
| August 15, 2022 |
Warrant, dated as of August 15, 2022, issued to the Jack W. Schuler Living Trust Exhibit 10.3 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE |
|
| August 15, 2022 |
Accelerate Diagnostics Reports Second Quarter 2022 Financial Results EX-99.1 6 tm2223444d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Accelerate Diagnostics Reports Second Quarter 2022 Financial Results TUCSON, Ariz., August 15, 2022 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2022. “In addition to a solid quarter, I am pleased to announce that we will be joining forces with Becton Di |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) June 29, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission F |
|
| May 27, 2022 |
Exhibit 1.01 Accelerate Diagnostics, Inc. Conflict Minerals Report For The Year Ended December 31, 2021 This Conflict Minerals Report for the year ended December 31, 2021 is submitted by Accelerate Diagnostics, Inc. (?Accelerate? or the ?Company?) as required by Section 13(p) of, and Rule 13p-1 under, the Securities Exchange Act of 1934, as amended (the ?Conflict Regulations?). The Company is not |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-31822 84-1072256 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Accelerate Diagnostics, Inc. 3950 South Country Club Road, Suite 470 T |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 S-8 POS 1 tm2215810d7s8pos.htm S-8 POS As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. 333-187439 Registration No. 333-199992 Registration No. 333-225585 Registration No. 333-233185 Registration No. 333-239052 Registration No. 333-182930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRAT |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. |
|
| May 20, 2022 |
As filed with the Securities and Exchange Commission on May 20, 2022 As filed with the Securities and Exchange Commission on May 20, 2022 Registration No. |
|
| May 20, 2022 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Accelerate Diagnostics, Inc. |
|
| May 17, 2022 |
Exhibit 10.1 ACCELERATE DIAGNOSTICS, INC. 2022 OMNIBUS EQUITY INCENTIVE PLAN EFFECTIVE DATE: May 12, 2022 Approved by SHAREholders: May 12, 2022 EXPIRATION DATE: May 12, 2032 ARTICLE 1 ESTABLISHMENT; PURPOSE; GLOSSARY 1.1 ESTABLISHMENT. Accelerate Diagnostics, Inc., a Delaware corporation (the ?Company?), hereby establishes the Accelerate Diagnostics, Inc. 2022 Omnibus Equity Incentive Plan (the ? |
|
| May 17, 2022 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE CERTIFICATE OF INCORPORATION OF ACCELERATE DIAGNOSTICS, INC. Accelerate Diagnostics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the ?Corporation?), hereby certifies as follows: FIRST: That the following resolutions were duly adopted by the Corporation?s Board of Directors, in ac |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 12, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission Fi |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCELERAT |
|
| May 16, 2022 |
Accelerate Diagnostics Reports First Quarter 2022 Financial Results Exhibit 99.1 Accelerate Diagnostics Reports First Quarter 2022 Financial Results TUCSON, Ariz., May 16, 2022 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the first quarter for the period ended March 31, 2022. ?First quarter financial results were consistent with our expectations,? commented Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) May 16, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission Fi |
|
| April 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 24, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| March 25, 2022 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is dated as of March 24, 2022, by and among Accelerate Diagnostics, Inc., a Delaware corporation (the ?Company?), and the purchaser identified on Annex I attached hereto (including its successors and assigns, a ?Purchaser?). WHEREAS, subject to the terms and conditions set forth in this Agreement and p |
|
| March 21, 2022 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 20, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| March 14, 2022 |
EXHIBIT 4.4 DESCRIPTION OF OUR CAPITAL STOCK REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General As of December 31, 2021, Accelerate Diagnostics, Inc. (?we?, ?us? or ?our?) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our common stock, par value $0.001 per share. Our authorized capital stock consists of 105 |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of regi |
|
| March 14, 2022 |
EX-21 3 axdx-12312021xexh21ng.htm EX-21 EXHIBIT 21 ACCELERATE DIAGNOSTICS, INC. LIST OF SUBSIDIARIES Legal Entity Jurisdiction/Domicile Accelerate Diagnostics UK Limited England Accelerate Diagnostics S.L. Spain Accelerate Diagnostics GmbH Germany Accelerate Diagnostics SARL France Accelerate Diagnostics S.r.l Italy Accelerate Diagnostics B.V. Netherlands Accelerate Diagnostics Holdings, LLC Unite |
|
| March 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) March 8, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission F |
|
| March 8, 2022 |
Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2021 Financial Results Exhibit 99.1 Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2021 Financial Results TUCSON, Ariz., March 8, 2022 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2021. Jack Phillips, Chief Executive Officer of Accelerate Diagnostics, Inc, commented, " the addition of new contracts, clinically live cu |
|
| February 24, 2022 |
PACB / Pacific Biosciences of California Inc / FEINBERG LARRY N - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 9* (EXIT FILING) Under the Securities Exchange Act of 1934 Accelerate Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69404D108 (CUSIP Number) February 18, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 11, 2022 |
PACB / Pacific Biosciences of California Inc / FEINBERG LARRY N - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 8* Under the Securities Exchange Act of 1934 Accelerate Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 69404D108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 9, 2022 |
Accelerate Diagnostics, Inc. 3950 South Country Club Road, Suite 470 Tucson, Arizona 85714 February 9, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Re: Accelerate Diagnostics, Inc. Registration Statement on Form S-3 File No. 333-262494 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursua |
|
| February 3, 2022 |
As filed with the Securities and Exchange Commission on February 3, 2022 As filed with the Securities and Exchange Commission on February 3, 2022 Registration No. |
|
| February 3, 2022 |
Exhibit 3.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF ACCELERATE DIAGNOSTICS, INC. February 2, 2022 Pursuant to the resolutions adopted on February 2, 2022 by the Board of Directors of Accelerate Diagnostics, Inc., a Delaware corporation (the ?Company?), the Company?s Amended and Restated Bylaws (the ?Bylaws?) are hereby amended as follows: 1. Section 3.02 of the Bylaws is replaced in |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) February 2, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| February 3, 2022 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Accelerate Diagnostics, Inc. |
|
| January 13, 2022 |
Exhibit 99.2 JPM HEALTHCARE CONFERENCE 2022 Jack Phillips President & CEO Accelerate Diagnostics, Inc January 2022 2 CAUTIONARY NOTE ON FORWARD - LOOKING STATEMENTS ? Copyright 2022 Accelerate Diagnostics, Inc. All Rights Reserved. The ?ACCELERATE DIAGNOSTICS? and ?ACCELERATE PHENO? and ?A CCE LERATE PHENOTEST? and ?ACCELERATE ARC? and diamond shaped logos and marks are registered trademarks of Ac |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) January 13, 2022 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| January 13, 2022 |
Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results Exhibit 99.1 Accelerate Diagnostics Announces Preliminary Fourth Quarter & Full-Year 2021 Financial Results TUCSON, Ariz., January 13, 2022 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the quarter and year ending December 31, 2021. Highlights for the fourth quarter and full-year 2021 are presented below. 2021 Fourth Quarter and Full-Year Financial |
|
| December 3, 2021 |
AXDX / Accelerate Diagnostics Inc / SCHULER JACK W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCEL |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) August 5, 2021 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission |
|
| November 12, 2021 |
Accelerate Diagnostics Reports Second Quarter 2021 Financial Results EX-99.1 2 tm2132529d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Accelerate Diagnostics Reports Second Quarter 2021 Financial Results TUCSON, Ariz., August 5, 2021 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter for the period ended June 30, 2021. “Second quarter and year to date financial results were consistent with our expectations,” commented Jac |
|
| November 12, 2021 |
Exhibit 99.2 Accelerate Diagnostics Inc. 2021 Third Quarter Results Conference Call Tuesday, November 09, 2021, 4:30 PM Eastern CORPORATE PARTICIPANTS Jack Phillips - President, Chief Executive Officer Steve Reichling - Chief Financial Officer Laura Pierson - Investor Relations 1 PRESENTATION Operator Good day, and welcome to the Accelerate Diagnostics Inc. 2021 Third Quarter Results Conference Ca |
|
| November 12, 2021 |
EX-99.2 3 tm2132529d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Accelerate Diagnostics, Inc. Second Quarter 2021 Earnings Call Thursday, August 05, 2021, 4:30 PM Eastern CORPORATE PARTICIPANTS Jack Phillips - President, Chief Executive Officer Steve Reichling - Chief Financial Officer Laura Pierson - Investor Relations 1 PRESENTATION Operator Hello, and welcome to Accelerate Diagnostics Inc. Second Quar |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) November 9, 2021 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| November 12, 2021 |
Accelerate Diagnostics Reports Third Quarter 2021 Financial Results Exhibit 99.1 Accelerate Diagnostics Reports Third Quarter 2021 Financial Results TUCSON, Ariz., November 9, 2021 - Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the third quarter for the period ended September 30, 2021, which remain subject to quarter end closing adjustments. ?The resurgence of COVID hospitalizations impacted our commercial execution |
|
| November 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 29, 2021 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| October 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) October 15, 2021 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commissio |
|
| October 5, 2021 |
EX-99 2 tm2129186d1ex1.htm EXHIBIT 1 EXHIBIT 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the undersigned parties hereby agrees to file jointly Amendment No. 9 to Schedule 13D (including any amendments thereto) (the “Statement”) with respect to the common stock, $0.001 per share par value (the “Common Stock”), |
|
| October 5, 2021 |
AXDX / Accelerate Diagnostics Inc / SCHULER JACK W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 29, 2021 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| September 23, 2021 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this ?Agreement?) is dated as of September 22, 2021, by and among Accelerate Diagnostics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on Annex I attached hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms an |
|
| September 23, 2021 |
Exhibit 10.3 Form of Exchange Agreement [ ], 202[1] Accelerate Diagnostics, Inc. 2.50% Convertible Senior Notes due 2023 The undersigned investor (the ?Investor?), for itself and on behalf of the beneficial owners listed on Exhibit A hereto (?Accounts?) for whom the Investor holds contractual and investment authority (each, including the Investor if it is a party exchanging Notes (as defined below |
|
| September 23, 2021 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF THE SERIES A PREFERRED STOCK OF ACCELERATE DIAGNOSTICS, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware, Accelerate Diagnostics, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?), in accordance with the provisions of Section 103 thereof, does hereby |
|
| September 23, 2021 |
Exhibit 10.1 RESCISSION AGREEMENT This Rescission Agreement (this ?Agreement?) is made and entered into as of September 17, 2021 (the ?Agreement Date?), by and among Accelerate Diagnostics, Inc., a Delaware corporation (the ?Company?), and the Tanya Eva Schuler Trust, the Therese Heidi Schuler Trust and Schuler Grandchildren LLC, an Illinois limited liability company (each a ?Purchaser?, together |
|
| September 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) September 17, 2021 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commiss |
|
| September 23, 2021 |
Exhibit 99.1 Accelerate Diagnostics Announces Agreements to Exchange Approximately $51 Million in Principal Amount of Its 2.50% Convertible Senior Notes due 2023 for Common Stock TUCSON, Ariz., September 23, 2021 ? Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 2.50% Convertible Sen |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-31822 ACCELERATE |
|
| August 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported) July 15, 2021 Accelerate Diagnostics, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) 001-31822 84-1072256 (Commission F |
